Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 6/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691702 | 0.82 | OPRM1 (0.60) | PARP10PARP15PARP2OPRM1OPRD1 | |
| SCHEMBL4963846 | 0.81 | OPRM1 (0.43) | PARP10PARP15PARP2OPRM1OPRD1 | |
| SCHEMBL4964061 | 0.80 | OPRM1 (0.41) | PARP10PARP15OPRM1OPRD1OPRK1 | |
| SCHEMBL4963704 | 0.79 | OPRM1 (0.43) | PARP10PARP15PARP2OPRM1OPRD1 | |
| SCHEMBL4964763 | 0.78 | OPRM1 (0.69) | PARP10OPRM1OPRD1OPRK1KMT2A | |
| SCHEMBL4963842 | 0.76 | OPRM1 (0.48) | PARP10PARP15OPRM1OPRD1OPRK1 | |
| SCHEMBL4965288 | 0.74 | OPRM1 (0.46) | OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL4964300 | 0.73 | OPRM1 (0.53) | PARP10OPRM1OPRD1OPRK1KMT2A | |
| SCHEMBL3693106 | 0.72 | OPRM1 (0.66) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3694870 | 0.72 | OPRM1 (0.65) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606275-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | claimed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | claimed |
| US-20060166987-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | claimed |
| EP-1606275-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080996-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| EP-1606275-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1606275-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396943-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060166987-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1606275-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080996-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166987-A1 | Opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | PARP10 4286/4885PARP15 4576/4885PARP2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.